VolitionRX (VNRX) Given a $10.00 Price Target at HC Wainwright

VolitionRX (NYSEAMERICAN:VNRX) has been given a $10.00 target price by research analysts at HC Wainwright in a research note issued on Tuesday. The brokerage currently has a “buy” rating on the medical research company’s stock. HC Wainwright’s target price points to a potential upside of 244.83% from the stock’s previous close.

VolitionRX (VNRX) traded down $0.13 during mid-day trading on Tuesday, reaching $2.90. The company had a trading volume of 80,277 shares, compared to its average volume of 126,026. The firm has a market cap of $76.90, a P/E ratio of -5.58 and a beta of -0.97. VolitionRX has a fifty-two week low of $2.08 and a fifty-two week high of $4.71.

VolitionRX (NYSEAMERICAN:VNRX) last released its earnings results on Thursday, November 9th. The medical research company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01).

Several hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp raised its position in VolitionRX by 177.1% during the second quarter. Bank of New York Mellon Corp now owns 30,376 shares of the medical research company’s stock valued at $108,000 after purchasing an additional 19,414 shares in the last quarter. Leisure Capital Management purchased a new stake in VolitionRX during the third quarter valued at about $193,000. Finally, Lagoda Investment Management L.P. raised its position in VolitionRX by 6.4% during the third quarter. Lagoda Investment Management L.P. now owns 3,356,754 shares of the medical research company’s stock valued at $8,828,000 after purchasing an additional 201,062 shares in the last quarter.

TRADEMARK VIOLATION WARNING: “VolitionRX (VNRX) Given a $10.00 Price Target at HC Wainwright” was posted by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was stolen and republished in violation of US and international copyright laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2018/02/06/volitionrx-vnrx-given-a-10-00-price-target-at-hc-wainwright.html.

VolitionRX Company Profile

VolitionRx Limited is a clinical-stage life sciences company. The Company is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The Company has developed approximately 30 blood-based assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease.

Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply